Supernus Pharmaceuticals Inc

Change company Symbol lookup

Select an option...

SUPN Supernus Pharmaceuticals Inc

DIS Walt Disney Co

BAC Bank of America Corp

GOOD Gladstone Commercial Corp

ADTN ADTRAN Inc

ALRM Alarm.com Holdings Inc

NLOK NortonLifeLock Inc

PROSY Prosus NV

IMBBY Imperial Brands PLC

VNTR Venator Materials PLC

Go

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.